Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

GH Research to Announce IND Status for GH001 - GH Research (NASDAQ:GHRS)

Summary by Benzinga
DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

GH Research stock rises on upcoming trial update (GHRS:NASDAQ)

GH Research (GHRS) stock jumped 20% after-hours ahead of its Jan 5 update on Phase 3 depression program and FDA IND status on GH001. Read more here.

·United States
Read Full Article
BenzingaBenzinga
Center

GH Research to Announce IND Status for GH001 - GH Research (NASDAQ:GHRS)

DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Friday, January 2, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

Stock Markets icon

Stock Markets

Dublin, Ireland icon

Dublin, Ireland

Business & Markets icon

Business & Markets

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal